An important mechanism behind the neural hyperactivity observed in mice with Alzheimer’s has been explained by researchers at the University of Tübingen. At the contact points between nerve cells, there is a malfunction in the intracellular calcium storage which is needed for signal transfer.
As a result, too many signal chemicals (neurotransmitters) are released into the synaptic cleft.
The study shows how new findings can lead to fresh approaches to treatment of the hereditary form of Alzheimer´s disease.
Alzheimer´s disease is the key cause of dementia in elderly patients. Those affected develop deficiencies in their abilities to learn, think logically, communicate, and to master the challenges of everyday life.
To find out more about how the disease comes about, the team at the University of Tübingen used mice, developing the same amyloid protein deposits in their brains as human patients, and which also suffer memory loss.
Several years ago, a team led by Professor Olga Garaschuk showed that in these mice, the disease coincided with a noticeable increase in nerve cell activity in the brain. There were similar findings in human Alzheimer’s patients.
Nerve Cell Hyperactivity
Communication between nerve cells in the brain is largely carried out via electrical signals. But at the synapse – the transfer point between one nerve cell and another – the signal switches to a chemical one.
Calcium plays an important role here; it helps to release messenger chemicals known as neurotransmitters. They dock onto the next nerve cell, where another electrical impulse is generated and sent on.
In this new study, Garaschuk found that in mouse models of Alzheimer’s disease showing this abnormal increase in brain nerve cell activity, calcium storage at the presynaptic side was dysregulated.
“This releases a larger amount of neurotransmitters into the cerebral cortex – which leads to hyperactivity in the nerve cells,”
Alzheimer’s occurs sporadically in humans, the greatest risk factor being age. Yet a proportion of Alzheimer’s patients also have a genetic tendency towards the disease. In this kind of Alzheimer´s, 90 percent of those affected have a mutation of the presenilin gene.
“Interestingly, in mice, one single copy of this kind of mutated gene is enough to cause hyperactivity due to calcium storage malfunction,”
Garaschuk said. Chemical agents which can empty the cell’s calcium storage or – as one clinically approved drug does – block the release of calcium from this store; they also suppress the cell hyperactivity.
“That leads to a normalisation of cerebral cortex functions,”
she added. The findings could play a role in the development of new treatments for Alzheimer’s disease.
Image: Amyloid proteins (plaques, blue) in the cerebral cortex of a mouse model of Alzheimer’s disease, surrounded by cortical immune cells (microglia, green). Activated microglia cells (positive for CD-68) are marked red. Credit: O. Garaschuk/PNAS